SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.94+2.1%12:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: opalapril who wrote (8409)1/22/1999 10:58:00 AM
From: aknahow   of 17367
 
You said, or were posting your thoughts:

"Assuming the criticality finding is based on the real threat of death from meningo, if the P-3 has been extended
because the total death rate has slowed, as many suppose, because of better diagnosis and nursing care, doesn't
that undercut the finding about criticality that got us the orphan drug status?"

Answer: No. If there are fewer deaths the drug becomes even more of an orphan drug. If death rate for a small number of cases was 20% and better treatment reduces it to 10% there is even less incentive to produce a drug for this indication alone.

You also posted:

"..the delay is due to the fact that NO
ONE TO WHOM BPI WAS ADMINISTERED HAS DIED."

The death rate would not have to be reduce to zero to prolong the trial. any efficacy, even efficacy not sufficient to gain approval would by having reduced deaths below expected deaths would extend the trial.

Remaining cash is a concern for almost every biotech, that does not yet have earnings. If the trial is successful there should be a better chance of financing on more favorable terms than in the past. And indeed a successful trial may get partners to agree to deals that a mutually beneficial rather than one sided.

:
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News